KS18 efficiently reduces Mcl-1 levels, whereas bortezomib obstructs proteasome function, and dexamethasone alters glucocorticoid receptor signaling, thus enhancing apoptotic stress on myeloma cells. The gene discussed is MCL1; the disease is plasma cell myeloma.